Perjeta US OK tops winning week for Genentech/Roche in breast cancer
This article was originally published in Scrip
Executive Summary
Topping off a successful week of having some of the most talked about data in Chicago at the annual meeting of the American Society of Clinical Oncology (ASCO) with the experimental "smart bomb" drug T-DM1 in HER2-positive metastatic breast cancer, Roche and its US unit Genentech gained the US FDA's approval on 8 June to market Perjeta (pertuzumab) as a therapy to treat the disease.